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There is no cure for schizophrenia. Accordingly, 
clinicians must do their best at managing the various 
symptoms that emerge during the course of the 
disease. Therefore, identiﬁ cation of putative risk factors 
that trigger relapse and contribute to poor prognosis 
is crucial. Because cannabis might contribute to the 
development of schizophrenia,1 the continued eﬀ ect of 
the drug on the course of the disease is of great clinical 
interest and a focus on how to improve outcomes in 
this disorder is essential. 
In their observational study, Tabea Schoeler and 
colleagues2 investigated the eﬀ ects of diﬀ erent 
patterns of cannabis (eg, use, frequency, and 
potency) on risk of relapse in patients with ﬁ rst 
episode psychosis in South London, UK. Findings 
showed that cannabis’ eﬀ ects on outcome varied 
depending on the particular cannabis-using proﬁ le of 
the individual. More speciﬁ cally, cannabis users who 
had continuous, high frequency and high potency 
exposure had the worst outcome, in terms of risk 
of relapse (OR 3·28, 95% CI 1·22–9·18), number of 
relapses (IRR 1·77, 95% CI 0·96–3·25), time to relapse 
(b –0·22, 95% CI –0·40 to –0·04), and more intense 
psychiatric care after the onset of psychosis compared 
with former users (OR 3·16, 95% CI 1·26–8·09). 
Further, high frequency, high potency users relapsed 
more quickly than did patients who consumed high 
potency cannabis at a lower frequency, hash-like 
cannabis users, and patients who were never (regular) 
cannabis users. 
This study oﬀ ers several strengths over other 
studies that have assessed the association between 
cannabis and outcome in patients with psychotic 
disorders. First, this study was prospective, and 
assessed cannabis use trajectories during the ﬁ rst 
2 years after the onset of psychosis. A major limitation 
of previous cross-sectional studies is their inability to 
diﬀ erentiate between cause and eﬀ ect. This caveat 
has led to the self-medication hypothesis,3 an over-
popularised explanation for addictive behaviours 
that  posits that cannabis is used by patients to help 
mitigate the negative eﬀ ects of the disorder as well as 
side eﬀ ects associated with antipsychotic treatment. 
Inconsistent with this idea, ﬁ ndings from Schoeler and 
colleagues showed that cannabis might contribute 
to symptomatology rather than alleviating it. This 
ﬁ nding underscores the importance of employing the 
appropriate temporal and longitudinal paradigms 
when assessing the eﬀ ects of cannabis on outcome in 
patients across the schizophrenia spectrum. 
Cannabis is a diﬃ  cult substance to quantify. 
Accordingly, the researchers aimed to assess cannabis 
exposure not only as a measure of continuity and 
frequency, but also with respect to potency. Cannabis 
is a very complex plant that can be bred to yield 
hundreds of strains, each with a unique combination 
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of cannabinoids. However, in most studies cannabis 
is conceptualised as a uniform drug. Cannabis varies 
substantially in the level of its two major cannabinoids: 
delta-9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD). Levels of CBD can range from almost zero to 
up to 40%.4 Notably, these two cannabinoids have 
opposing properties and thus can produce divergent 
eﬀ ects. For example, THC is often associated with 
deleterious eﬀ ects such as impaired cognition, anxiety, 
and psychotic-like symptoms, whereas CBD has been 
associated with antipsychotic and anxiolytic-like 
eﬀ ects, and might even oﬀ er neuroprotection.5–7 In 
view of these diﬀ erences, the researchers aimed to 
decipher the type of cannabis their study sample 
consumed by asking participants to describe their 
preferred type of cannabis: skunk-like (high THC) or 
hash-like (high CBD).
The investigators should be commended for 
confronting this issue; however, the manner in which 
it was addressed raises concern. Can patients with 
ﬁ rst episode psychosis accurately identify the type 
of cannabis they are using? Objective quantitative 
analysis might more reliably capture cannabis 
potency versus qualitative methods. Additionally, 
the assessment of potency as a binary variable might 
be too simplistic for such a complex plant in view of 
the fact that eﬀ ects of cannabis depend not only on 
THC potency, but also on the ratio of THC to CBD.8 
The importance of studying the type of cannabis of 
users has recently been highlighted in the scientiﬁ c 
literature.9 As cannabis research progresses, hopefully 
investigators will begin to regard cannabis as a 
conglomerate of cannabinoids rather than one 
homogeneous substance. 
Findings presented by Schoeler and colleagues2 
support the idea that clinicians should actively 
intervene and help patients to quit cannabis and 
remain abstinent. Nevertheless, the investigators 
suggest a possible harm reduction model in which 
interventions could focus on persuading cannabis 
users to reduce use or shift to less potent forms of 
cannabis, especially patients with psychosis who are 
otherwise unable to stop using cannabis. However, the 
proposal of such a framework might be problematic. 
In the same respect that not all cannabis is the same, 
not all users are the same. That is, skunk users might 
diﬀ er from hash users. Additionally, if high potency 
users switch to low potency cannabis, conceivably, 
they might use more cannabis in an attempt to chase 
the familiar high. Better characterisation of these 
diﬀ erent users is warranted to develop appropriate 
and tailored interventions.
The investigators’ results highlight the association 
between cannabis and subsequent relapse in patients 
with ﬁ rst episode psychosis, especially in those who are 
frequently exposed to high potency preparations. As a 
result of genetic modiﬁ cation and advanced methods 
of cultivation, high THC cannabis is becoming 
the norm, therefore addressing the increased risks 
implicated with these strains of cannabis should be of 
high priority. 
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